The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...

Growing evidence suggests the gut microbiome may influence how patients respond to GLP 1 obesity drugs. Researchers are ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...